Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently expe...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica
Main Authors: Boudny, Miroslav, Zemanova, Jana, Khirsariya, Prashant, Borsky, Marek, Verner, Jan, Cerna, Jana, Oltova, Alexandra, Seda, Vaclav, Mraz, Marek, Jaros, Josef, Jaskova, Zuzana, Spunarova, Michaela, Brychtova, Yvona, Soucek, Karel, Drapela, Stanislav, Kasparkova, Marie, Mayer, Jiri, Paruch, Kamil, Trbusek, Martin
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6959166/
https://ncbi.nlm.nih.gov/pubmed/30975914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.203430
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items